Literature DB >> 2650898

Ketamine: an update on the first twenty-five years of clinical experience.

D L Reich1, G Silvay.   

Abstract

In nearly 25 years of clinical experience, the benefits and limitations of ketamine analgesia and anaesthesia have generally been well-defined. The extensive review of White et al. and the cardiovascular review of Reves et al. are broad in their scope and have advanced the understanding of dissociative anaesthesia. Nevertheless, recent research continues to illuminate different aspects of ketamine pharmacology, and suggests new clinical uses for this drug. The identification of the N-methylaspartate receptor gives further support to the concept that ketamine's analgesic and anaesthetic effects are mediated by separate mechanisms. The stereospecific binding of (+)ketamine to opiate receptors in vitro, more rapid emergence from anaesthesia, and the lower incidence of emergence sequelae, make (+)ketamine a promising drug for future research. Clinical applications of ketamine that have emerged recently, and are likely to increase in the future, are the use of oral, rectal, and intranasal preparations for the purposes of analgesia, sedation, and anaesthetic induction. Ketamine is now considered a reasonable option for anaesthetic induction in the hypotensive preterm neonate. The initial experience with epidural and intrathecal ketamine administration has not been very promising but the data are only preliminary in this area. The use of ketamine in military and catastrophic settings is likely to become more common. The clinical availability of midazolam will complement ketamine anaesthesia in several ways. This rapidly metabolized benzodiazepine reduces ketamine's cardiovascular stimulation and emergence phenomena, and does not have active metabolites. It is dispensed in an aqueous medium, which is usually non-irritating on intravenous injection, unlike diazepam. The combination of ketamine and midazolam is expected to achieve high patient acceptance, which never occurred with ketamine as a sole agent. Finally, it is necessary to point out the potential for abuse of ketamine. While ketamine is not a controlled substance (in the United States), the prudent physician should take appropriate precautions against the unauthorized use of this drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650898     DOI: 10.1007/BF03011442

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  113 in total

1.  The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.

Authors:  A D Ivankovich; A A El-Etr; G F Janeczko; J P Maronic
Journal:  Anesth Analg       Date:  1975 Jan-Feb       Impact factor: 5.108

2.  Effect of anesthetic induction regimens on oxygen saturation in cyanotic congenital heart disease.

Authors:  R S Laishley; F A Burrows; J Lerman; W L Roy
Journal:  Anesthesiology       Date:  1986-12       Impact factor: 7.892

3.  [Intracranial pressure during ketamine administration with spontaneous respiration. An animal experimental model].

Authors:  E Pfenninger; F W Ahnefeld; A Grünert
Journal:  Anaesthesist       Date:  1985-04       Impact factor: 1.041

4.  Changes in anterior fontanel pressure in preterm neonates receiving isoflurane, halothane, fentanyl, or ketamine.

Authors:  R H Friesen; R E Thieme; A T Honda; J E Morrison
Journal:  Anesth Analg       Date:  1987-05       Impact factor: 5.108

5.  Rectal ketamine for induction of anaesthesia in children.

Authors:  J Idvall; J Holasek; P Stenberg
Journal:  Anaesthesia       Date:  1983-01       Impact factor: 6.955

6.  The effects of ketamine on the canine coronary circulation.

Authors:  G Smith; J Thorburn; J P Vance; D M Brown
Journal:  Anaesthesia       Date:  1979-06       Impact factor: 6.955

7.  [Smooth induction of anaesthesia in children by means of oral or rectal ketamine-dehydrobenzperidol application (author's transl)].

Authors:  J Cetina
Journal:  Anaesthesist       Date:  1982-06       Impact factor: 1.041

8.  Epidural ketamine for postoperative analgesia.

Authors:  M Naguib; Y Adu-Gyamfi; G H Absood; H Farag; H K Gyasi
Journal:  Can Anaesth Soc J       Date:  1986-01

9.  [Ketamine via rectal route for the induction of pediatric anesthesia].

Authors:  J M Malaquin
Journal:  Cah Anesthesiol       Date:  1984-09

10.  Ketamine-atracurium by continuous infusion as the sole anesthetic for pulmonary surgery.

Authors:  D I Rees; M L Howell
Journal:  Anesth Analg       Date:  1986-08       Impact factor: 5.108

View more
  102 in total

1.  Ketamine for procedural pain relief in newborn infants.

Authors:  E Saarenmaa; P J Neuvonen; P Huttunen; V Fellman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-07       Impact factor: 5.747

Review 2.  Cognitive dysfunction in schizophrenia: unifying basic research and clinical aspects.

Authors:  R W McCarley; M A Niznikiewicz; D F Salisbury; P G Nestor; B F O'Donnell; Y Hirayasu; H Grunze; R W Greene; M E Shenton
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

Review 3.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 4.  Pharmacodynamic considerations for moderate and deep sedation.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2012

Review 5.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

6.  Analgesic effects of ketamine infusion therapy in korean patients with neuropathic pain: A 2-week, open-label, uncontrolled study.

Authors:  Jin Gu Kang; Chul Joong Lee; Tae Hyeong Kim; Woo Seok Sim; Byung Seop Shin; Sang Hyun Lee; Francis Sahngun Nahm; Pyung Bok Lee; Yong Chul Kim; Sang Chul Lee
Journal:  Curr Ther Res Clin Exp       Date:  2010-04

Review 7.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

8.  Ketamine Attenuates the ACTH Response to Hypoxia in Late-Gestation Ovine Fetus.

Authors:  Eileen I Chang; Charles E Wood
Journal:  Neonatology       Date:  2015-02-18       Impact factor: 4.035

9.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

10.  Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures.

Authors:  R Abrams; J E Morrison; A Villasenor; D Hencmann; M Da Fonseca; W Mueller
Journal:  Anesth Prog       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.